首页> 外文期刊>Trials >Direct improvement of quality of life in colorectal cancer patients using a tailored pathway with quality of life diagnosis and therapy (DIQOL): study protocol for a randomised controlled trial
【24h】

Direct improvement of quality of life in colorectal cancer patients using a tailored pathway with quality of life diagnosis and therapy (DIQOL): study protocol for a randomised controlled trial

机译:使用量身定制的途径进行生活质量诊断和治疗(DIQOL),直接改善结直肠癌患者的生活质量:一项随机对照试验的研究方案

获取原文
           

摘要

Background Medical treatment in patient-centred care in oncology is broadly managed and regulated in terms of guideline development, cancer centres, and quality assurance by cancer registries. In contrast to this quality management cycle (PDCA), there are no equal standards for patient-reported outcomes like quality of life (QoL). Therefore, the Tumour Centre Regensburg e.V., a population-based regional cancer registry covering a population of more than 2.2 million people in the Upper Palatinate and Lower Bavaria, Germany, designed and implemented a QoL pathway. In a complex intervention with QoL diagnosis and therapy (multidimensional therapeutic network), effectiveness for patients with breast cancer has been demonstrated. To provide local tailored QoL diagnosis and therapy to other cancer patients as well, external validity needs to be extended by adapting the QoL pathway to another tumour entity. Methods/Design The QoL pathway will be tested for colorectal cancer patients in a pragmatic randomised controlled trial. Two hundred twenty primary colorectal cancer patients, surgically treated in one of four hospitals, will be included. QoL is measured in all patients 0, 3, 6, 12, and 18?months after surgery (European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30, QLQ-CR29). In the intervention group, QoL scores are transformed into a QoL profile. This is sent to the coordinating practitioner (general practitioner, internist, or oncologist) with an expert report including treatment recommendations for QoL deficits. The control group receives routine follow-up care attending the guideline recommendations for colorectal cancer without profile or expert report. At the primary endpoint (12?months), the rates of patients with diseased QoL in both groups are compared. Discussion This randomised trial is the first complex intervention investigating the effectiveness of an intervention with QoL diagnosis and tailored QoL therapy in colorectal cancer patients. The results will show if this QoL pathway improves the patients’ QoL during follow-up care of their disease. Trial registration ClinicalTrials.gov, NCT02321813 (registered December 2014).
机译:背景技术在指南制定,癌症中心和癌症登记机构的质量保证方面,对肿瘤科以患者为中心的医疗进行了广泛的管理和监管。与该质量管理周期(PDCA)相比,没有像患者生活质量(QoL)这样的患者报告结果具有相同的标准。因此,Regensburg e.V.肿瘤中心是一个以人口为基础的区域性癌症登记处,设计并实施了QoL途径,该登记处覆盖了德国上普法尔茨州和下巴伐利亚州的220万人。在QoL诊断和治疗(多维治疗网络)的复杂干预中,已证明对乳腺癌患者有效。为了向其他癌症患者也提供本地量身定制的QoL诊断和治疗,需要通过使QoL途径适应另一个肿瘤实体来扩展外部有效性。方法/设计将在一项实用的随机对照试验中对结肠直肠癌患者的QoL途径进行测试。将包括在四家医院之一中接受手术治疗的220名原发性大肠癌患者。在手术后0、3、6、12和18个月的所有患者中测量QoL(欧洲癌症研究与治疗组织(EORTC)QLQ-C30,QLQ-CR29)。在干预组中,QoL分数将转换为QoL资料。这将与专家报告一起发送给协调医生(普通医生,内科医生或肿瘤科医生),其中包括针对QoL缺乏症的治疗建议。对照组接受常规随访,遵循大肠癌指南建议,但无简介或专家报告。在主要终点(12个月),比较两组患者QoL的患病率。讨论该随机试验是第一个复杂的干预措施,旨在研究在大肠癌患者中采用QoL诊断和量身定制的QoL治疗的干预措施的有效性。结果将显示该QoL途径是否在患者的疾病后续护理期间改善患者的QoL。试验注册ClinicalTrials.gov,NCT02321813(2014年12月注册)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号